Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients September 16, 2026
Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC September 16, 2026
FAILED TRIAL: SERENA-4 trial of Etcamah + palbociclib did not meet primary objective of statistically significant PFS improvement September 16, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 16, 2026
Results from Ph 3 Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO September 16, 2026
Positive results announced from registrational Ph 1/2 ARROS-1 trial of Jideytro (zidesamtinib) in patients with advanced or metastatic TKI-naive ROS1-positive NSCLC September 16, 2026
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed SCLC in China September 16, 2026
RYBREVANT® (amivantamab-vmjw) + chemo delivers long median OS in EGFR exon 20 insertion mutation-positive NSCLC September 16, 2026
Ph 3 data for Tam-Peli shows significantly improved OS in Chinese patient population with relapsed SCLC September 16, 2026
Tagrisso demonstrated eight-year survival in early-stage EGFR-mutated lung cancer in ADAURA Ph 3 trial September 16, 2026
Enhertu demonstrated a median PFS of 14.3 months IN 1L HER2-mutant advanced NSCLC in DESTINY-Lung04 Ph 3 trial September 16, 2026
INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Ph 2 HNSCC Study September 9, 2026
Positive Topline Results Announced from Ph 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and PFS in RRMM Patients September 9, 2026
Imfinzi + Imdelltra demonstrated statistically significant OS & PFS improvement in 1L ES-SCLC September 9, 2026
Positive Topline Results Announced from Registrational Ph 2 QUINTESSENTIAL Trial of GPRC5D-Directed CAR T Cell Therapy Arlocabtagene Autoleucel September 9, 2026
Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions September 9, 2026
100% Three-Year DFS announced with TG4050 and Ph 1 Results Published in Nature Communications September 9, 2026
NEJM Publishes Ph 1/2 Clinical Data on RASONQUE™ (daraxonrasib) in Metastatic NSCLC September 9, 2026
Ivonescimab Meets OS Key Secondary Endpoint in Interim Analysis of Ph 3 HARMONi-2 Study, Demonstrating Statistically Significant Benefit Versus Pembrolizumab in 1L PD-L1-Positive NSCLC September 9, 2026
SANOVO Trial Demonstrated Significant PFS Benefit of ORPATHYS + TAGRISSO in 1L Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China September 2, 2026
Ziihera® (zanidatamab-hrii) + Chemo Demonstrates Statistically Significant OS Benefit vs Trastuzumab + Chemo in 1L HER2+ Advanced GEA September 2, 2026
Confirmed Durable Partial Response Achieved in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy September 2, 2026
Ivonescimab + Chemo Global Ph 3 HARMONi Primary Analysis Results Published in The Lancet Oncology September 2, 2026
